Victoria Tutag Lehr, Pharm.D.

Victoria Tutag Lehr, Pharm.D.

Professor (Clinical)

Office Location

EACPHS, Room 4144





Pharmacy Practice

Research website

Victoria Tutag Lehr, Pharm.D.

Degrees and Certifications

  • Bachelor of Science, Pharmacy: Ferris State University, Big Rapids, MI 1978
  • Doctor of Pharmacy: Wayne State University; Detroit, MI 1987
  • Licensure: Pharmacist State of Michigan (active); Preceptor (active); State of Michigan Pharmacist Controlled Substance (active)
  • Medication Therapy Management Training Program WSU 2015 

Positions and Employment

  • 2017-Present - Professor (Clinical), Wayne State University
  • 2006-2017 - Associate Professor, Wayne State University
  • 2000-2006 - Assistant Professor, Wayne State University
  • 2003-2006 - Clinical Preceptor, Butler University
  • 1993-2000 - Clinical Adjunct Faculty, Wayne State University
  • 1991-2000 - Clinical Adjunct Faculty, Ferris State University

Awards and Honors

  • 2022 - Student Senate faculty award: naloxone in student housing
  • 2020 - Faculty of the Year Award from class of 2021
  • 2018 - ACCP Research award (2ndplace poster): Lead (Pb) inhibits insulin-activated AKT signaling and reduces glycogen in rat liver. 

Professional Memberships

  • 2020-present - American Society of Addiction Medicine
  • 2016-present - Pediatric Pharmacy Advocacy Group
  • 2015-present - American Society Health Systems Pharmacists
  • 2010-present - Michigan Society of Health Systems Pharmacists
  • 2010-present - Oakland County Pharmacists Association
  • 2009-present - Michigan Pharmacist Association
  • 2000-present - American College of Clinical Pharmacy
  • 2006-2020 - American Association of Colleges of Pharmacy

Primary Research Interest

  • Pediatric pain assessment and management
  • Opioid overdose prevention
  • Adverse drug reactions
  • Lead and hepatic effects in children

Funded Research

AmerisourceBergen 2019 Opioid Resource Grant Program
01/31/2020-02/01/2021) $79,849.00 Role: Co-I 10% support
Pharmacists CARE Program in Dependence and Recovery

MDHHS Injury and Violence Prevention Unit
(4/01/2019-8/31/2019) $59,998.00 Role: PI
Naloxone and Responsiveness of Michigan Pharmacists
Aim: To characterize practice of Michigan community pharmacists with respect to naloxone distribution and education.

HRSA Graduate Psychology Education (GPE) Program grant to Vhs Children’s Hospital of Michigan
(9/1/2019 – 8/31/2022)
Award No: 1D40HP33377-01-00
Clinical Psychology Internship Training in Behavioral Health Care for High Need Pediatric Populations
Funding for four CHM Psychology Interns as well as faculty development with a focus on prevention and treatment of substance abuse and opioid use disorder.

Blue Cross Blue Shield of Michigan Foundation
(7/01/18-6/31/19) • Role: Co-PI
High risk prescribing of controlled medications
Aim: The goal is to examine high-risk opioid prescribing as defined by opioid dosage, duration or concurrent use with other medications longitudinally and across geographic areas to assess the need for specific interventions and the impact of current national, state, and payer policies to address the opioid overdose epidemic in Southeastern Michigan.

Center Student Academic Success, Wayne State University
(08/15/2013-05/14/2019) • Role: Principal Investigator
2nd year Pharmacy Student Learning Community Program
Aim: to maintain the Learning Community to optimize student success by emphasizing skills in pharmacology and pharmacotherapeutics. Funding for 1 academic year.

Faculty Research Award Program-EACPHS
(2/1/2012-2/1/2013) • Role: Co-Investigator
Effect of group exercise on chronic neck pain in individuals over 50 years of age
Aim: to examine the effect of group Pilates and Yoga exercise classes on function, range of motion, endurance, postural position, pain, medication use and balance in adults over 50 years of age with chronic moderate to severe cervical spine pain.

Blue Cross Blue Shield of Michigan Foundation
(7/01/09-12/31/11) • Role: Investigator
Diagnosing Adverse Drug Reactions (ADR) in the Pediatric Intensive Care Unit (PICU)
Aim: to assess incidence, risk factors and costs of ADRs in a PICU in a prospective study. Results used to develop a valid, reliable, and easy-to-use algorithm specifically for diagnosing ADRs in PICUs using a novel mathematical approach.

Children’s Research Center of Michigan
(7/01/08-7/01/10) • Role: Investigator
Mechanisms of Lead Effects on Hepatic Glycogen Metabolism
Aims: 1. elucidate molecular mechanisms lead effects on hepatic glycogen and glucose metabolism; 2. determine lead exposure effects on corresponding hepatic gene expression and, 3. determine effects of lead exposure on growth hormones.

The Gerber Foundation
(06/01/07-06/01/09) • Role: Investigator
An Adverse Drug Reaction Assessment Tool for Newborns in NICUs – A Pilot Study
Aim: to develop and validate a tool for assessing ADRs in the neonatal population, and to examine the impact of the tool on decreasing drug-related morbidity and mortality.

The Gerber Foundation
(1/01/05-1/01/08) • Role: Principal Investigator
Skin blood flow changes using Laser Doppler Imager for assessment of pain and analgesia in newborn infants
Aims: 1. determine the relationship between skin blood flow response and clinical measures of pain (NIPS scores, heart rate, respiratory rate, oxygen saturation) in the newborn infant using the heel lance model. 2. determine the temporal skin blood flow response to painful stimuli using the heel lance model. 3. evaluate effect of oral sucrose 24% solution on skin blood flow response during heel lance.

Ferndale Labs, Inc.
(4/01/01-5/01/03) • Role: Principal Investigator
Lidocaine 4% cream (LMX4) for anesthesia for newborn circumcision
Aim: study to evaluate the effect of lidocaine 4% cream for topical anesthesia
during newborn circumcision compared with 2.5 % lidocaine and 2.5% prilocaine eutectic mixture cream and dorsal penile nerve block as measured by heart rate, respiratory rate, oxygen saturation, infant cry analysis, and neonatal facial coding system scores.

Other research

Pharmacists' knowledge of naloxone administration in the community
(05-2016 –10-2016) • Role: Co-Principal Investigator
Aim: to identify gaps pharmacists’ knowledge regarding dispensing of naloxone in the community as pilot for education program development. 

Experience with Dexmedetomidine for Sedation of Children undergoing Imaging
(09-2009–09-2016) • Role: Principal Investigator
Aim: to evaluate the safety and efficacy of dexmedetomidine for sedation of pediatric patients during imaging at Children’s Hospital of Michigan. 

Recent Publications


  • Tutag Lehr V, Potts G, Lulic-Botica M. Topical Medications for Pediatric Dermatologic Conditions. In: Aranda JV, VandenAnker J, eds. Pediatric Pharmacology: Therapeutic Principles in Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2021:251-270.
  • Chemtob S, Reese J, Lapointe A, Nadeau-Vallee M, Tutag Lehr V. Nonsteroidal anti-inflammatory drugs. In: Aranda JV, Vande Anker J, eds. Pediatric Pharmacology: Therapeutic Principles in Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2021:553-585.
  • Tutag Lehr V, Williams M. Pediatric Anticonvulsants. In: Aranda JV, Vande Anker J, eds. Pediatric Pharmacology: Therapeutic Principles in Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2021:473-498
  • Tutag Lehr V, Lulic-Botica M, Valencia GB, Calo J, Aranda JV. Analgesia and sedation in the newborn infant. In: Ramasethu J, Rais-Bahrami K, eds. Atlas of Procedures in Neonatology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2019:1-7.

Refereed Journals

  • Tutag Lehr V, Meloche L, Stokan E. Naloxone provision in the community pharmacy: survey of Michigan pharmacists. International Journal of Health Policy and Management (under review)
  • Tutag Lehr V, Tomkinson P, Opara O, Meloche L. Student pharmacist perceptions of community overdose response training. Substance Abuse Treatment, Prevention, and Policy (under review).
  • Tutag Lehr V, Nolan C. Community Pharmacists' Knowledge and Perceptions of Buprenorphine for Patients with Opioid Use Disorder [published online ahead of print, 2023 Jan 6]. J Addict Med. 2023;10.1097/ADM.0000000000001135. 
  • Obarzanek L, Wu W, Tutag-Lehr V. Opioid Management of Dyspnea at End of Life: A Systematic Review [published online ahead of print, 2022 Nov 28]. J Palliat Med. 2022;10.1089/jpm.2022.0311. doi:10.1089/jpm.2022.0311
  • Mohammad IN, Berry D, Tutag Lehr V. Opioid Use Disorder care during COVID-19:call for action. JACCP 2021; 11. doi 10.1002/jac5.1556.
  • Arfken C, Tutag Lehr V. Commercial and public payer opioid analgesic prescribing policies: a case study. Substance Abuse Treatment, Prevention, and Policy 2021; 16:4 Impact Factor 2.31
  • Stewart B, Thomas R, Tutag Lehr V. Pharmacists’ knowledge, support, and perceived roles providing naloxone in the community. Currents in Pharmacy Teaching and Learning 2018; Aug 10(8):1013-102. Impact Factor: 0.60

Abstracts Published in Academic Journals

  • Arfken CL, Tutag Lehr V. Did commercial and Medicaid opioid analgesic policies change after CDC treatment of chronic pain guidelines was revised? J Mental Health Policy Economics 2023; 26(Suppl 1):S5.
  • Tutag Lehr V, Opara O, Tomkinson P, Meloche L. Student pharmacist perceptions of community overdose response training JACCP 2022; 5(12):1482.
  • Tutag Lehr V, Matthew M, Mastrandrea N, Leff T. Lead (Pb) inhibits insulin-activated AKT signaling and reduces glycogen in rat liver. Pharmacotherapy 2018; 38(7):62e. (ACCP 2nd place poster May 2018)

Courses taught by Victoria Tutag Lehr, Pharm.D.

Spring-Summer Term 2024

Winter Term 2024

Spring-Summer Term 2023

Winter Term 2023

Spring-Summer Term 2022

← Return to listing